Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The art of gene therapy for glioma: a review of the challenging road to the bedside.

Tobias A, Ahmed A, Moon KS, Lesniak MS.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):213-22. doi: 10.1136/jnnp-2012-302946. Epub 2012 Sep 19. Review.

2.

Gene therapy and targeted toxins for glioma.

King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG.

Curr Gene Ther. 2005 Dec;5(6):535-57. Review.

3.

Gene therapy and targeted toxins for glioma.

Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR.

Curr Gene Ther. 2011 Jun;11(3):155-80. Review.

4.

Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Kroeger KM, Muhammad AK, Baker GJ, Assi H, Wibowo MK, Xiong W, Yagiz K, Candolfi M, Lowenstein PR, Castro MG.

Discov Med. 2010 Oct;10(53):293-304. Review.

5.

Gene therapy for malignant glioma.

Okura H, Smith CA, Rutka JT.

Mol Cell Ther. 2014 Jul 8;2:21. doi: 10.1186/2052-8426-2-21. eCollection 2014. Review.

6.

Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.

Juratli TA, Schackert G, Krex D.

Pharmacol Ther. 2013 Sep;139(3):341-58. doi: 10.1016/j.pharmthera.2013.05.003. Epub 2013 May 18. Review.

PMID:
23694764
7.

Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR.

Expert Opin Biol Ther. 2014 Sep;14(9):1241-57. doi: 10.1517/14712598.2014.915307. Epub 2014 Apr 29. Review.

8.

Targeting role of glioma stem cells for glioblastoma multiforme.

Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD, Hu SJ.

Curr Med Chem. 2013;20(15):1974-84. Review.

PMID:
23317162
9.

A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.

Ahmed AU, Thaci B, Tobias AL, Auffinger B, Zhang L, Cheng Y, Kim CK, Yunis C, Han Y, Alexiades NG, Fan X, Aboody KS, Lesniak MS.

J Natl Cancer Inst. 2013 Jul 3;105(13):968-77. doi: 10.1093/jnci/djt141.

10.

Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J.

Neurosurg Rev. 2008 Apr;31(2):141-55; discussion 155. doi: 10.1007/s10143-008-0121-0. Epub 2008 Feb 8. Review.

11.

Gene therapy for malignant glioma: current clinical status.

Pulkkanen KJ, Yla-Herttuala S.

Mol Ther. 2005 Oct;12(4):585-98. Review.

12.

Oncolytic HSV-1 for the treatment of brain tumours.

Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ.

Herpes. 2006 Nov;13(3):66-71. Review.

PMID:
17147910
13.

Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.

Auffinger B, Ahmed AU, Lesniak MS.

Front Oncol. 2013 Feb 25;3:32. doi: 10.3389/fonc.2013.00032. eCollection 2013.

14.

Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT Jr.

Neurosurgery. 2012 Sep;71(3):741-8; discussion 748. doi: 10.1227/NEU.0b013e318260fd73.

15.

Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.

Ulasov IV, Tyler MA, Rivera AA, Nettlebeck DM, Douglas JT, Lesniak MS.

J Med Virol. 2008 Sep;80(9):1595-603. doi: 10.1002/jmv.21264.

16.

Advances in oncolytic virus therapy for glioma.

Haseley A, Alvarez-Breckenridge C, Chaudhury AR, Kaur B.

Recent Pat CNS Drug Discov. 2009 Jan;4(1):1-13. Review.

17.

CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.

Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, Gillespie GY, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Cancer Gene Ther. 2009 Oct;16(10):794-805. doi: 10.1038/cgt.2009.23. Epub 2009 Apr 10.

18.

Cell- and peptide-based immunotherapeutic approaches for glioma.

Yamanaka R.

Trends Mol Med. 2008 May;14(5):228-35. doi: 10.1016/j.molmed.2008.03.003. Epub 2008 Apr 9. Review.

PMID:
18403264
19.

A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.

Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS.

Mol Pharm. 2011 Oct 3;8(5):1559-72. doi: 10.1021/mp200161f. Epub 2011 Jun 30.

20.

Cancer stem cells: the final frontier for glioma virotherapy.

Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS.

Stem Cell Rev. 2011 Mar;7(1):119-29. doi: 10.1007/s12015-010-9132-7. Review.

Supplemental Content

Support Center